Rapid Biomarker Analysis at the Point of Care using Droplet Scientific Technology
Droplet Scientific, a pioneering MedTech company, is making strides in the healthcare industry with its innovative point-of-care analyzer. The company's first product has successfully completed animal testing trials and is currently being used in research settings.
As the team gears up for clinical trials, slated to begin shortly, they are actively seeking investment and partners to accelerate the development of their devices through clinical validation and regulatory approval. With a projected market launch in 2028, this groundbreaking technology is set to transform the way biomarkers are monitored in healthcare.
Currently, biomarkers like lactate levels, glucose levels, hormone levels, and therapeutic drug levels are measured in clinical settings by healthcare professionals who send blood samples to laboratories for testing. However, this process can take hours to days, slowing effective treatment and using valuable resources.
Droplet Scientific's medical-grade monitor aims to address these issues by delivering precise and personalized healthcare interventions based on accurate data 24/7 for selected biomarkers. The company's point-of-care analyzer can continuously measure and monitor various biomarkers in near real-time, providing a 'snapshot' of the patient's current condition at the time of testing.
This purpose-driven effort is aimed at bridging critical gaps in healthcare and significantly improving the quality of life for numerous patients and healthcare professionals. Doctors and patients are empowered with real-time biomarker data, enabling faster and more informed health decisions.
The accuracy of Droplet Scientific's platform technology is comparable to currently available lab equipment, making it a promising solution for the major bottleneck and risk point in hospital treatments – the lack of real-time patient health and treatment monitoring.
Private clinical settings have been identified as the initial customer cohort for the product. The University of Southampton has also confirmed they will be licensing the IP for Droplet Scientific.
For more information about Droplet Scientific and their groundbreaking technology, please visit their website or connect with them directly. Co-founder and CTO Junda Niu believes the technology can make a 10x difference in emergency and intensive care healthcare treatment.
[1] [Link to Reference 1] [2] [Link to Reference 2] [3] [Link to Reference 3] [4] [Link to Reference 4]
- Droplet Scientific, a pioneering MedTech company, is seeking investment and partners to accelerate the development of their innovative point-of-care analyzer, which aims to revolutionize the healthcare industry by providing real-time biomarker data for selected medical-conditions.
- The accuracy of Droplet Scientific's technology is comparable to current lab equipment, offering a promising solution to the major bottleneck in hospital treatments – the lack of real-time patient health monitoring.
- The company's point-of-care analyzer can continuously measure and monitor various biomarkers in near real-time, empowering doctors and patients with the ability to make faster and more informed health decisions.
- The University of Southampton has confirmed they will be licensing the IP for Droplet Scientific, with private clinical settings identified as the initial customer cohort for their groundbreaking technology, which is set to transform the field of health-and-wellness, therapies-and-treatments, and technology-based medical research.
